Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Scott D Abbott"'
Autor:
George Grunberger, Cheryl R. Rosenfeld, Bruce W. Bode, Scott D. Abbott, Carla Nikkel, Leon Shi, Poul Strange
Publikováno v:
Drugs - Real World Outcomes, Vol 7, Iss 1, Pp 31-40 (2019)
Abstract Background V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia ris
Externí odkaz:
https://doaj.org/article/28f840a6feea4b70b5b2d5296aef74f3
Autor:
Cheryl R. Rosenfeld, Poul Strange, Bruce W. Bode, Carla Nikkel, George Grunberger, Scott D. Abbott, Leon Shi
Publikováno v:
Drugs-Real World Outcomes
Drugs-Real World Outcomes, Vol 7, Iss 1, Pp 31-40 (2019)
Drugs-Real World Outcomes, Vol 7, Iss 1, Pp 31-40 (2019)
Background V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia risk in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d16d2ad87f6ed01f775f5eb363dda1b1
http://europepmc.org/articles/PMC7060972
http://europepmc.org/articles/PMC7060972
Autor:
H. Courtenay Harrison, Leon Shi, Mark J. Cziraky, Matt Nguyen, Scott D Abbott, T. Wasser, Lynn Nowak, Beverly Everitt, Elizabeth Apgar, Kay Larholt, Poul Strange
Publikováno v:
Journal of Health Economics and Outcomes Research
Background: Many patients with type 2 diabetes mellitus (T2DM) do not have adequate glycemic control, leading to poor patient outcomes and high healthcare costs. Objective: This prospective pragmatic clinical trial evaluated V-Go, a wearable insulin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fff2d070be307ce01ef7b4d58ec1bf2c
https://doi.org/10.36469/9731
https://doi.org/10.36469/9731
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Michael Grabner,1 Yong Chen,2 Matthew Nguyen,3 Scott D Abbott,3 Ralph Quimbo1 1HealthCore, Inc., Wilmington, DE, USA; 2Merck and Co., Inc., Whitehouse Station, NJ, USA; 3Valeritas, Inc., Bridgewater, NJ, USA Objective: To inform the design and assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db1f91a8904efab733d1c852d862d36c
https://pubmed.ncbi.nlm.nih.gov/24098085
https://pubmed.ncbi.nlm.nih.gov/24098085
Publikováno v:
Drugs-Real World Outcomes
Background Diabetes is a chronic condition and when poorly controlled can lead to complications and death. Patients with glycated hemoglobin (A1C) measures >9 % are at significant risk for diabetes-related complications impacting the patient’s qual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6a349160c8172c6e6daee843c6ad222